The rising incidence of kidney disease due to increasing obesity, high blood pressure and diabetes is forming a gigantic market for new renal disease treatments, according to a new report by GlobalData.
Cancer cell signalling has long been an attractive target for oncology drug development. Increased activation of cell survival signalling cascades promotes tumour cell growth and makes cancer cells difficult to kill. Inhibiting proteins that are involved in these survival pathways is one strategy to selectively destroy cancerous cells. The mitogen activated protein kinase (MAPK) pathway is one such signalling cascade that, when activated, promotes cell survival. Preclinical research has found that this pathway is activated in most melanomas; consequently, one of the key kinases involved in this pathway, MEK, has become the focus of targeted therapies for the treatment of melanoma. MEK, which stands for MAPK/ ERK kinase and is also known as MAPKK, has several known structural variants called ‘isoforms’ which play different roles within the cell. Isoforms 1 and 2, referred to as MEK1/2, are the isoforms associated with MEK’s ability to promote cell survival.
Quotient Clinical, a provider of specialist early stage drug development services, and Capsugel, a manufacturer of innovative dosage solutions for the healthcare industry, have announced a collaboration to enable the rapid development and clinical assessment of lipid-based formulations. Together, the companies will use their technology and expertise to address the drug delivery challenges of poorly soluble molecules with limited oral bioavailability.